Key facts
- This page summarizes Matthew Hawryluk's Form 4 filing for Gritstone bio, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 May 2024, 21:56.
Matthew Hawryluk - 15 May 2024 Form 4 Insider Report for Gritstone bio, Inc.
- Reporting relationship
- EVP, CHIEF BUSINESS OFFICER
- Issuer ticker
- N/A
- Reported as of
- 15 May 2024
- Net transaction value
- -$6,929
- SEC form
- 4
- Accepted by SEC
- 17 May 2024, 21:56:19 UTC
- Prior SEC filing
- 12 Apr 2024
- Next SEC filing
- 11 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vassiliki Economides, Attorney-in-Fact for Matthew Hawryluk
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew Hawryluk filed Form 4 for Gritstone bio, Inc. on 17 May 2024.
Change
- Previous filing in this sequence was filed on 12 Apr 2024.
- Current net transaction value: -$6,929.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GRTS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +19,149
- Change %
- +6.3%
- Price
- $0.000000
- Shares after
- 323,190
- Date
- 15 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2
GRTS
transaction
Common Stock
Sale
- Transaction value
- $6,929
- Shares
- -9,259
- Change %
- -2.9%
- Price
- $0.7483
- Shares after
- 313,931
- Date
- 16 May 2024
- Ownership
- Direct
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GRTS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +180,000
- Change %
- Price
- $0.000000
- Shares after
- 180,000
- Date
- 15 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 180,000
- Exercise price
- $0.7500
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents Performance Stock Units ("PSUs") granted on March 22, 2024 that were earned by the Reporting Person as a result of the achievement of certain performance criteria as certified by the Issuer's Board of Directors on May 15, 2024. The PSUs vest over one year; 1/2 vested on May 15, 2024, and thereafter the remaining 1/2 will vest on May 15, 2025, subject to the continuing service of the Reporting Person on such vesting date. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
Includes 273,719 Restricted Stock Units ("RSUs") and PSUs which are subject to vesting.
Footnote F3
The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of PSUs.
Footnote F4
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.735 to $0.7616 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F5
The option vests as to 1/2 of the total grant on September 30, 2024, with the remainder of grant vesting on September 30, 2025, subject to the continued service of the Reporting Person on each vesting date.